SpecificiT wins seed funding from AmorChem, Sanderling, Accel-Rx
Montréal-based biopharmaceutical startup SpecificiT Pharma Inc has raised an undisclosed seed-stage financing. Existing investor AmorChem, a Canadian life sciences seed fund, backed the round alongside new investors, Sanderling Ventures and Accel-Rx Health Sciences Accelerator. With the deal, Dr. Pierre Beauparlant, a Sanderling venture partner, will become the company's CEO. SpecificiT, first financed by AmorChem in 2013, is developing cellular therapies for the treatment of hematological cancers. It will use the funds raised to complete manufacturing and process development and add to the management team.
11 September 2017•5 mins read
